The application of clinical proteomics to cancer and other diseases

Clinical Chemistry and Laboratory Medicine

Volumn 41, Issue 12, 2003, Pages 1562-1570

  Clarke, William ^a   Zhang, Zhen ^a   Chan, Daniel W ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

2 D Gel electrophoresis; Cancer proteomics; Clinical proteomics; Mass spectrometry

Indexed keywords

CALBINDIN; CYCLOSPORIN; PROTEIN;

ALZHEIMER DISEASE; ANALYTIC METHOD; BIOINFORMATICS; BREAST CANCER; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL RESEARCH; HEART VENTRICLE HYPERTROPHY; HUMAN; MASS SPECTROMETRY; NEPHROTOXICITY; NEUROMUSCULAR DISEASE; ORGAN TRANSPLANTATION; OVARY CANCER; PHARMACODYNAMICS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SAMPLING; TWO DIMENSIONAL GEL ELECTROPHORESIS;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHEMISTRY, CLINICAL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; MASS SPECTROMETRY; NEOPLASMS; PROTEOMICS;

EID: 0346097940     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2003.239     Document Type: Review

References (82)

1. Huber LA. Is proteomics heading in the wrong direction? Nat Rev Mol Cell Biol 2003; 4:74-80.
2. Pennington SR, Wilkins MR, Hochstrasser DF, Dunn MJ. Trends Cell Biol 1997; 7:168.
3. Peng J, Gygi SP. Proteomics: the move to mixtures. J Mass Spectrom 2001; 36:1083-91.
4. Rai AJ, Chan DW. Clinical proteomics: new developments in clinical chemistry. Lab Med 2001; 25:399-403.
5. Palmer-Toy DE, Kuzdzal S, Chan DW. Proteomic approaches to tumor marker discovery. In: Diamandis EP, Fritsche HA, Lilja H, Chan DW, Schwartz MK, editors. Tumor markers: physiology, pathobiology, technology, and clinical applications. Washington, DC: AACC Press, 2002:391-400.
6. Hancock W, Apffel A, Chakel J, Hahnenberger K, Choudhary G, Traina JA, et al. Integrated genomic/proteomic analysis. Anal Chem 1999; 71:742A-748A.
7. Zhou H, Watts JD, Aebersold R. A systematic approach to the analysis of protein phosphorylation. Nat Biotechnol 2001; 19:375-8.
8. Hancock WS, Wu SL, Shieh P. The challenges of developing a sound proteomics strategy. Proteomics 2002; 2:352-9.
9. Aebersold R. A mass spectrometric journey into protein and proteome research. J Am Soc Mass Spectrom 2003; 14:685-95.
10. Corthals GL, Wasinger VC, Hochstrasser DF, Sanchez JC. The dynamic range of protein expression: a challenge for proteomic research. Electrophoresis 2000; 21:1104-15.
11. Harry JL, Wilkins MR, Herbert BR, Packer NH, Gooley AA, Williams KL. Proteomics: capacity versus utility. Electrophoresis 2000; 21:1071-81.
12. O'Farrell PH. High resolution two-dimensional electrophoresis of proteins. J Biol Chem 1975; 250:4007-21.
13. Klose J. Protein mapping by combined isoelectric focusing and electrophoresis of mouse tissues. A novel approach to testing for induced point mutations in mammals. Human-genetik 1975; 26:231-43.
14. Issaq HJ. The role of separation science in proteomics research. Electrophoresis 2001; 22:3629-38.
15. Gygi SP, Aebersold R. Mass spectrometry and proteomics. Curr Opin Chem Biol 2000; 4:489-94.
16. Lopez MF. Better approaches to finding the needle in a haystack: optimizing proteome analysis through automation. Electrophoresis 2000; 21:1082-93.
17. Karas M, Hillenkamp F. Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. Anal Chem 1988; 60:2299-301.
18. Fenn JB, Mann M, Meng CK, Wong SF, Whitehouse CM. Electrospray ionization for mass spectrometry of large biomolecules. Science 1989; 246:64-71.
19. Merchant M, Weinberger SR. Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 2000; 21:1164-77.
20. Issaq HJ, Veenstra TD, Conrads TP, Felschow D. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun 2002; 292:587-92.
21. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 2003; 422:198-207.
22. Clarke W, Silverman BC, Zhang Z, Chan DW, Klein AS, Molmenti EP. Characterization of renal allograft rejection by urinary proteomic analysis. Ann Surg 2003; 237:660-4; discussion 664-5.
23. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002; 48:1296-304.
24. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359:572-7.
25. Chakraborty A, Regnier FE. Global internal standard technology for comparative proteomics. J Chromatogr A 2002; 949:173-84.
26. Cottrell JS. Protein identification by peptide mass finger-printing. Pept Res 1994; 7:115-24.
27. Gevaert K, Vandekerckhove J. Protein identification methods in proteomics. Electrophoresis 2000; 21:1145-54.
28. Larsen MR, Roepstorff P. Mass spectrometric identification of proteins and characterization of their post-translational modifications in proteome analysis. Fresenius J Anal Chem 2000; 366:677-90.
29. Xiong L, Regnier FE. Use of a lectin affinity selector in the search for unusual glycosylation in proteomics. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 782:405-18.
30. Mann M, Wilm M. Error-tolerant identification of peptides in sequence databases by peptide sequence tags. Anal Chem 1994; 66:4390-9.
31. Fenyo D, Qin J, Chait BT. Protein identification using mass spectrometric information. Electrophoresis 1998; 19:998-1005.
32. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 1999; 20:3551-67.
33. Yates JR 3rd. Database searching using mass spectrometry data. Electrophoresis 1998; 19:893-900.
34. Chakravarti DN, Chakravarti B, Moutsatsos I. Informatic tools for proteome profiling. Biotechniques 2002; Suppl: 4-10, 12-5.
35. Ito T, Sakaki Y. Toward genome-wide scanning of gene expression: a functional aspect of the Genome Project. Essays Biochem 1996; 31:11-21.
36. Going JJ, Gusterson BA. Molecular pathology and future developments. Eur J Cancer 1999; 35:1895-904.
37. Wallrapp C, Muller-Pillasch F, Micha A, Wenger C, Geng M, Solinas-Toldo S, et al. Strategies for the detection of disease genes in pancreatic cancer. Ann N Y Acad Sci 1999; 880:122-46.
38. Vapnik VN. Statistical learning theory. New York: John Wiley & Sons, 1998:401-440.
39. Zhang Z, Page G, Zhang H. Applying classification separability analysis to microarray data. In: Lin SM JK, editor. Method of microarray data analysis: papers from CAMDA '00. Boston: Kluwer Academic Publishers, 2001:25-26.
40. Rai AJ, Zhang Z, Rosenzweig J, Shih Ie M, Pham T, Fung ET, et al. Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med 2002; 126:1518-26.
41. Sorace JM, Zhan M. A data review and re-assessment of ovarian cancer serum proteomic profiling. BMC Bioinformatics 2003; 4:24.
42. Holdaway RM, White MW. Computational neural networks: enhancing supervised learning algorithms via self-organization. Int J Biomed Comput 1990; 25:151-67.
43. Erwin E, Obermayer K, Schulten K. Self-organizing maps: stationary states, metastability and convergence rate. Biol Cybern 1992; 67:35-45.
44. Holland JH, editor. Adaptation in natural and artificial systems: an introductory analysis with applications to biology, control, and artificial intelligence, 3rd ed. Cambridge, MA: MIT Press, 1994.
45. Rockhill B. Proteomic patterns in serum and identification of ovarian cancer. Lancet 2002; 360:169; author reply 170-1.
46. Elwood M. Proteomic patterns in serum and identification of ovarian cancer. Lancet 2002; 360:170; author reply 170-1.
47. Pearl DC. Proteomic patterns in serum and identification of ovarian cancer. Lancet 2002; 360:169-70; author reply 170-1.
48. Diamandis EP. Proteomic patterns in serum and identification of ovarian cancer. Lancet 2002; 360:170; author reply 170-1.
49. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002; 62:3609-14.
50. Yasui Y, Pepe M, Thompson ML, Adam BL, Wright GL Jr, Qu Y, et al. A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection. Biostatistics 2003; 4:449-63.
51. Djavan B, Mazal P, Zlotta A, Wammack R, Ravery V, Remzi M, et al. Pathological features of prostate cancer detected on initial and repeat prostate biopsy: results of the prospective European Prostate Cancer Detection study. Prostate 2001; 47:111-7.
52. Meehan KL, Holland JW, Dawkins HJ. Proteomic analysis of normal and malignant prostate tissue to identify novel proteins lost in cancer. Prostate 2002; 50:54-63.
53. Sauter ER, Zhu W, Fan XJ, Wassell RP, Chervoneva I, Du Bois GC. Proteomic analysis of nipple aspirate fluid to detect biologic markers of breast cancer. Br J Cancer 2002; 86:1440-3.
54. Paweletz CP, Trock B, Pennanen M, Tsangaris T, Magnant C, Liotta LA, et al. Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Dis Markers 2001; 17:301-7.
55. Varnum SM, Covington CC, Woodbury RL, Petritis K, Kangas LJ, Abdullah MS, et al. Proteomic characterization of nipple aspirate fluid: identification of potential biomarkers of breast cancer. Breast Cancer Res Treat 2003; 80:87-97.
56. Wulfkuhle JD, Sgroi DC, Krutzsch H, McLean K, McGarvey K, Knowlton M, et al. Proteomics of human breast ductal carcinoma in situ. Cancer Res 2002; 62:6740-9.
57. Hondermarck H, Dolle L, El Yazidi-Belkoura I, Vercoutter-Edouart AS, Adriaenssens E, Lemoine J. Functional proteomics of breast cancer for signal pathway profiling and target discovery. J Mammary Gland Biol Neoplasia 2002; 7:395-405.
58. Aicher L, Wahl D, Arce A, Grenet O, Steiner S. New insights into cyclosporine A nephrotoxicity by proteome analysis. Electrophoresis 1998; 19:1998-2003.
59. Stanley BA, Neverova I, Brown HA, Van Eyk JE. Optimizing protein solubility for two-dimensional gel electrophoresis analysis of human myocardium. Proteomics 2003; 3:815-20.
60. McDonough JL, Neverova I, Van Eyk JE. Proteomic analysis of human biopsy samples by single two-dimensional electrophoresis: Coomassie, silver, mass spectrometry, and Western blotting. Proteomics 2002; 2:978-87.
61. You SA, Archacki SR, Angheloiu G, Moravec CS, Rao S, Kinter M, et al. Proteomic approach to coronary atherosclerosis shows ferritin light chain as a significant marker: evidence consistent with iron hypothesis in atherosclerosis. Physiol Genomics 2003; 13:25-30.
62. Arnott D, O'Connell KL, King KL, Stults JT. An integrated approach to proteome analysis: identification of proteins associated with cardiac hypertrophy. Anal Biochem 1998; 258:1-18.
63. Macri J, Rapundalo ST. Application of proteomics to the study of cardiovascular biology. Trends Cardiovasc Med 2001; 11:66-75.
64. Lubec G, Krapfenbauer K, Fountoulakis M. Proteomics in brain research: potentials and limitations. Prog Neurobiol 2003; 69:193-211.
65. van den Heuvel LP, Farhoud MH, Wevers RA, van Engelen BG, Smeitink JA. Proteomics and neuromuscular diseases: theoretical concept and first results. Ann Clin Biochem 2003; 40:9-15.
66. Choe LH, Dutt MJ, Relkin N, Lee KH. Studies of potential cerebrospinal fluid molecular markers for Alzheimer's disease. Electrophoresis 2002; 23:2247-51.
67. Ballantyne CM. Newer risk markers and surrogate end-points in atherosclerosis management. Clin Cardiol 2001; 24:III13-7.
68. Bohring C, Krause W. Immune infertility: towards a better understanding of sperm (auto)-immunity: the value of proteomic analysis. Hum Reprod 2003; 18:915-24.
69. Maguire PB, Fitzgerald DJ. Platelet proteomics. J Thromb Haemost 2003; 1:1593-601.
70. Ota J, Yamashita Y, Okawa K, Kisanuki H, Fujiwara S, Ishikawa M, et al. Proteomic analysis of hematopoietic stem cell-like fractions in leukemic disorders. Oncogene 2003; 22:5720-8.
71. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2003; 2:566-80.
72. Colburn WA. Biomarkers in drug discovery and development: from target identification through drug marketing. J Clin Pharmacol 2003; 43:329-41.
73. Bruneau JM, Maillet I, Tagat E, Legrand R, Supatto F, Fudali C, et al. Drug induced proteome changes in Candida albicans: comparison of the effect of beta(1,3) glucan synthase inhibitors and two triazoles, fluconazole and itraconazole. Proteomics 2003; 3:325-36.
74. Chen ST, Pan TL, Tsai YC, Huang CM. Proteomics reveals protein profile changes in doxorubicin-treated MCF-7 human breast cancer cells. Cancer Lett 2002; 181:95-107.
75. Witzmann FA, Grant RA. Pharmacoproteomics in drug development. Pharmacogenomics J 2003; 3:69-76.
76. Wilkins MR. What do we want from proteomics in the detection and avoidance of adverse drug reactions. Toxicol Lett 2002; 127:245-9.
77. Daniel H. Genomics and proteomics: importance for the future of nutrition research. Br J Nutr 2002; 87 Suppl 2: S305-11.
78. van Ommen B, Stierum R. Nutrigenomics: exploiting systems biology in the nutrition and health arena. Curr Opin Biotechnol 2002; 13:517-21.
79. O'Connor CD, Adams P, Alefounder P, Farris M, Kinsella N, Li Y, et al. The analysis of microbial proteomes: strategies and data exploitation. Electrophoresis 2000; 21:1178-86.
80. Huang SH, Triche T, Jong AY. Infectomics: genomics and proteomics of microbial infections. Funct Integr Genomics 2002; 1:331-44.
81. Ostrowski LE, Blackburn K, Radde KM, Moyer MB, Schlatzer DM, Moseley A, et al. A proteomic analysis of human cilia: identification of novel components. Mol Cell Proteomics 2002; 1:451-65.
82. Hubbard MJ, Kon JC. Proteomic analysis of dental tissues. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 771:211-20.